Lucid Diagnostics Stock Analysis
LUCD Stock | USD 0.77 0.02 2.37% |
Lucid Diagnostics is undervalued with Real Value of 1.66 and Target Price of 4.36. The main objective of Lucid Diagnostics stock analysis is to determine its intrinsic value, which is an estimate of what Lucid Diagnostics is worth, separate from its market price. There are two main types of Lucid Diagnostics' stock analysis: fundamental analysis and technical analysis.
The Lucid Diagnostics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Lucid Diagnostics' ongoing operational relationships across important fundamental and technical indicators.
Lucid |
Lucid Stock Analysis Notes
About 61.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.12. Lucid Diagnostics had not issued any dividends in recent years. Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. To find out more about Lucid Diagnostics contact Lishan MD at 917 813 1828 or learn more at https://www.luciddx.com.Lucid Diagnostics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Lucid Diagnostics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Lucid Diagnostics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Lucid Diagnostics generated a negative expected return over the last 90 days | |
Lucid Diagnostics has some characteristics of a very speculative penny stock | |
Lucid Diagnostics has high historical volatility and very poor performance | |
Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (52.67 M) with loss before overhead, payroll, taxes, and interest of (3.24 M). | |
Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Lucid Diagnostics has a poor financial position based on the latest SEC disclosures | |
Roughly 61.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from benzinga.com: Tesla To 370 Here Are 10 Top Analyst Forecasts For Monday |
Lucid Diagnostics Upcoming and Recent Events
12th of March 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
12th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Lucid Largest EPS Surprises
Earnings surprises can significantly impact Lucid Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.35 | -0.4 | -0.05 | 14 | ||
2022-08-15 | 2022-06-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2022-05-16 | 2022-03-31 | -0.3 | -0.35 | -0.05 | 16 |
Lucid Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Virtu Financial Llc | 2024-06-30 | 14.2 K | Northern Trust Corp | 2024-09-30 | 13.1 K | First Manhattan Co. Llc | 2024-09-30 | 12.6 K | Resources Investment Advisors Inc | 2024-09-30 | 11.2 K | Byrne Asset Management Llc | 2024-06-30 | 11 K | Tower Research Capital Llc | 2024-09-30 | 6.1 K | Advisor Group Holdings, Inc. | 2024-09-30 | 3.1 K | Wells Fargo & Co | 2024-09-30 | 2.5 K | Jones Financial Companies Lllp | 2024-09-30 | 1.9 K | Luminus Management, Llc | 2024-09-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 560.9 K |
Lucid Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 46.61 M.Lucid Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.04) | (2.14) | |
Return On Capital Employed | 22.96 | 24.10 | |
Return On Assets | (1.93) | (2.03) | |
Return On Equity | 22.79 | 23.93 |
Management Efficiency
Lucid Diagnostics has return on total asset (ROA) of (1.0102) % which means that it has lost $1.0102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0783) %, meaning that it created substantial loss on money invested by shareholders. Lucid Diagnostics' management efficiency ratios could be used to measure how well Lucid Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Lucid Diagnostics' Return On Equity is projected to increase based on the last few years of reporting. At present, Lucid Diagnostics' Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.09, whereas Total Assets are forecasted to decline to about 26.8 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | (0.06) | (0.05) | |
Tangible Book Value Per Share | (0.09) | (0.08) | |
Enterprise Value Over EBITDA | (1.11) | (1.05) | |
Price Book Value Ratio | (25.48) | (26.75) | |
Enterprise Value Multiple | (1.11) | (1.05) | |
Price Fair Value | (25.48) | (26.75) | |
Enterprise Value | 55.2 M | 52.5 M |
Lucid Diagnostics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Operating Margin (9.98) | Beta 1.416 | Return On Assets (1.01) | Return On Equity (10.08) |
Technical Drivers
As of the 16th of December 2024, Lucid Diagnostics secures the Standard Deviation of 3.02, insignificant risk adjusted performance, and Mean Deviation of 2.29. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lucid Diagnostics, as well as the relationship between them. Please verify Lucid Diagnostics variance, as well as the relationship between the maximum drawdown and skewness to decide if Lucid Diagnostics is priced some-what accurately, providing market reflects its recent price of 0.7713 per share. As Lucid Diagnostics is a penny stock we also strongly advise to check its jensen alpha numbers.Lucid Diagnostics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Lucid Diagnostics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Lucid Diagnostics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Lucid Diagnostics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lucid Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lucid Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lucid Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lucid Diagnostics Outstanding Bonds
Lucid Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lucid Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lucid bonds can be classified according to their maturity, which is the date when Lucid Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
ALUFP 65 15 JAN 28 Corp BondUS549463AC10 | View | |
Alcatel Lucent USA Corp BondUS549463AE75 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Lucid Diagnostics Predictive Daily Indicators
Lucid Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lucid Diagnostics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lucid Diagnostics Forecast Models
Lucid Diagnostics' time-series forecasting models are one of many Lucid Diagnostics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lucid Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Lucid Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Lucid Diagnostics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lucid shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lucid Diagnostics. By using and applying Lucid Stock analysis, traders can create a robust methodology for identifying Lucid entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (21.69) | (22.78) | |
Operating Profit Margin | (19.97) | (20.97) | |
Net Loss | (21.69) | (22.78) | |
Gross Profit Margin | (1.46) | (1.54) |
Current Lucid Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lucid analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lucid analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
4.36 | Strong Buy | 6 | Odds |
Most Lucid analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Lucid stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Lucid Diagnostics, talking to its executives and customers, or listening to Lucid conference calls.
Lucid Stock Analysis Indicators
Lucid Diagnostics stock analysis indicators help investors evaluate how Lucid Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lucid Diagnostics shares will generate the highest return on investment. By understating and applying Lucid Diagnostics stock analysis, traders can identify Lucid Diagnostics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 22.5 M | |
Total Stockholder Equity | -2.3 M | |
Capital Lease Obligations | 1.3 M | |
Property Plant And Equipment Net | 2.6 M | |
Cash And Short Term Investments | 18.9 M | |
Net Invested Capital | -7 M | |
Cash | 18.9 M | |
50 Day M A | 0.9062 | |
Net Interest Income | -108 K | |
Total Current Liabilities | 29.4 M | |
Investments | -249 K | |
Interest Expense | 416 K | |
Stock Based Compensation | 6.8 M | |
Common Stock Shares Outstanding | 41.8 M | |
Free Cash Flow | -33 M | |
Operating Income | -48.5 M | |
Other Current Assets | 2.9 M | |
Accounts Payable | 1.1 M | |
Net Debt | -3.6 M | |
Depreciation | 2.5 M | |
Other Operating Expenses | 50.9 M | |
Non Current Assets Total | 5.2 M | |
Liabilities And Stockholders Equity | 27.3 M | |
Non Currrent Assets Other | 1.1 M |
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |